Longeveron INC Form 4 insider transactions

A Longeveron Inc. director acquired common stock and warrants under a pre-arranged trading plan.

Longeveron Inc. has granted 109,000 stock options to its Chief Scientific Officer, Director, and 10% Owner, Joshua Hare, with an exercise price of $1.47, vesting quarterly over three years starting October 1, 2025.

Longeveron Inc. Director Soffer Rock received an award of 17,000 time-based vesting Restricted Stock Units, increasing his total beneficial ownership to 226,034 shares.

Longeveron Inc.'s Chief Medical Officer, Nataliya Agafonova, was granted 102,000 Restricted Stock Units and 34,000 stock options, increasing her beneficial ownership.

Longeveron Inc. Director Roger Joseph Hajjar was awarded 17,000 Class A Common Stock Restricted Stock Units, increasing his beneficial ownership to 33,000 shares.

Paul T. Lehr, General Counsel and Secretary of Longeveron Inc., has been granted 102,000 Restricted Stock Units and 34,000 stock options, increasing his beneficial ownership.

Longeveron Inc.'s Chief Financial Officer, Lisa Locklear, was granted 102,000 Restricted Stock Units and 34,000 stock options, aligning her interests with long-term company performance.

Longeveron Inc.'s CTO and SVP of CMC, Devin Blass, was granted 102,000 Restricted Stock Units and options to purchase 34,000 shares of Class A Common Stock.

Longeveron Inc. Director Baluch Khoso was awarded 17,000 Class A Common Stock Restricted Stock Units on July 15, 2025, increasing his total beneficial ownership to 40,750 shares.

Longeveron Inc.'s Chief Executive Officer, Mohamed Wa'el Ahmed Hashad, was granted 180,000 Restricted Stock Units and options to purchase 60,000 shares of Class A Common Stock.

Longeveron Inc. Director Richard N. Kender reported the acquisition of 17,000 Class A Common Stock shares through a Restricted Stock Unit award, increasing his total beneficial ownership to 33,000 shares.

Longeveron Inc. Director Neha J. Motwani was awarded 17,000 Restricted Stock Units (RSUs) on July 15, 2025, increasing her direct beneficial ownership to 33,000 shares.

Longeveron Inc. Director Ursula Ungaro was awarded 17,000 Class A Common Stock shares as time-based vesting Restricted Stock Units, increasing her beneficial ownership to 41,000 shares.

Longeveron Inc.'s CTO and SVP of CMC, Devin Blass, reported a future disposition of 4,599 Class A Common Stock shares on July 1, 2025, to cover tax obligations related to a restricted stock unit award.

Longeveron Inc.'s CEO, Mohamed Wa'el Ahmed Hashad, disposed of 13,146 shares of Class A Common Stock at $1.28 per share on July 1, 2025, to cover tax obligations related to a restricted stock unit award vesting.

Longeveron Inc.'s Chief Financial Officer, Lisa Locklear, reported the withholding of 7,431 shares of Class A Common Stock on July 1, 2025, to cover tax obligations related to the vesting of a restricted stock unit award.

Longeveron Inc.'s General Counsel and Secretary, Paul T. Lehr, reported the disposition of 1,562 shares of Class A Common Stock at $1.28 per share to cover tax obligations related to a restricted stock unit vesting.

Longeveron Inc.'s Chief Medical Officer, Nataliya Agafonova, reported a future disposition of 7,431 shares of Class A Common Stock to cover tax obligations related to a restricted stock unit award vesting, effective July 1, 2025.

Longeveron Inc.'s Chief Scientific Officer, Director, and 10% Owner, Joshua Hare, reported the acquisition of 49,219 stock options with an exercise price of $1.28, which vested immediately on July 1, 2025.

Longeveron Inc.'s General Counsel, Paul T. Lehr, reported the award and vesting of 163,043 restricted stock units and the subsequent sale of 64,158 shares to cover tax obligations, with all transactions scheduled for June 23, 2025, an unusual future date relative to the filing date.

Longeveron Inc. has filed an amended Form 4 to correct the transaction date for a stock option grant to Chief Scientific Officer Joshua Hare and confirm shareholder approval for an increase in shares available under its 2021 Incentive Award Plan.

Longeveron Inc. has granted 184,878 stock options to Chief Scientific Officer Joshua Hare, which will fully vest on July 1, 2025, following shareholder approval of an increase in shares available under the company's incentive plan.

Longeveron Inc. Director and 10% owner, Rock Soffer, reported the sale of 21,000 shares of Class A Common Stock over two days in late May 2025, reducing his direct beneficial ownership to 209,034 shares.

Longeveron Inc. Director Rock Soffer has reported the sale of 2,000 shares of the company's Class A Common Stock at a price of $1.32 per share, as disclosed in a recent SEC Form 4 filing.

Joshua Hare, Chief Scientific Officer and Director at Longeveron Inc., sold 5,250 shares of Class A Common Stock at a weighted average price of $1.4033 on May 16, 2025.

Nataliya Agafonova, Chief Medical Officer of Longeveron Inc., reports disposition of shares to cover tax obligations related to vesting of restricted stock units.

Lisa Locklear, CFO of Longeveron Inc., reports the withholding of shares to cover tax obligations related to a restricted stock unit vesting.

Longeveron Inc. CEO Mohamed Wa'el Ahmed Hashad disposed of 13,384 shares of Class A Common Stock on April 1, 2025, to satisfy tax obligations related to a restricted stock unit award.

Paul T. Lehr, General Counsel and Secretary of Longeveron Inc., reports the disposal of 1,599 shares to cover tax obligations related to vesting restricted stock units.

Joshua Hare, Chief Scientific Officer of Longeveron Inc., reports the acquisition of stock options exercisable for 71,254 shares of common stock.